OneSource Speciality Pharma receives SFDA approval for its generic Ozempic | Capital Market News

OneSource Speciality Pharma has received approval from the Saudi Food and Drug Authority (SFDA) to commercially distribute a generic version of Ozempic (semaglutide) in Saudi Arabia. The company will partner with Hikma Pharmaceuticals PLC (Hikma) for commercialization across the Middle East and North Africa (MENA) region.

Expanding Access to GLP-1 Therapies

This approval marks a significant step for OneSource into the Saudi Arabian market, which is a major hub for GLP-1 therapies. The partnership with Hikma is intended to increase access to affordable generic alternatives for patients in the region, capitalizing on growing demand for these treatments.

Manufacturing and Distribution

OneSource will manufacture and supply the semaglutide from its facility in Bengaluru. Hikma, identified as the largest pharmaceutical company in MENA based on sales, will leverage its established commercial network and relationships to distribute the medication through both private and institutional channels.

Did You Know? Hikma Pharmaceuticals PLC will be the exclusive commercialization partner for OneSource Speciality Pharma in the Middle East and North Africa (MENA) region.

Expert Insight: The approval and subsequent partnership demonstrate a strategic move to address the increasing global demand for GLP-1 therapies by providing more affordable access through generic alternatives, particularly in a key regional market like Saudi Arabia.

Frequently Asked Questions

What has OneSource Speciality Pharma received approval for?

OneSource Speciality Pharma has received Saudi Food and Drug Authority (SFDA) approval for its generic Ozempic (semaglutide).

Who is OneSource’s commercialization partner?

Hikma Pharmaceuticals PLC (Hikma) is OneSource’s exclusive commercialization partner for the Middle East and North Africa (MENA) region.

Where will the semaglutide be manufactured?

The semaglutide will be manufactured at OneSource’s facility in Bengaluru.

How might this approval impact access to GLP-1 therapies in the region?